CIRM Funded Clinical Trials

Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.

Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$17,725,734
Trial Sponsor:
Caladrius Biosciences
Trial Stage: 
Phase 3
Trial Status: 
Terminated
Targeted Enrollment:
250
ClinicalTrials.gov ID: